Fosun International (SEHK:656) issued new earnings guidance for the first half of 2026, projecting profit attributable to owners of the parent of RMB 1.5b to RMB 1.8b, which is sharply above the prior year period.
See our latest analysis for Fosun International.
The earnings guidance has arrived alongside improving short term momentum, with a 1 month share price return of 10.17% and a 3 month share price return of 8.03%. However, the 1 year total shareholder return is down 19.71%, so Fosun International still carries a mixed longer term track record.
If this guidance has you thinking about what else might be moving, it could be a good time to broaden your watchlist with the 106 top founder-led companies
Fosun International now points to stronger profitability, yet the share price is only just starting to react. The key issue for you is whether this recent move already reflects that improvement or leaves meaningful value on the table.
Most Popular Narrative: 12.5% Undervalued
Fosun International last closed at HK$4.44, while the most followed narrative puts fair value at HK$5.08, based on a detailed long term earnings and margin path using a 13.03% discount rate.
The group's strong health segment momentum, underpinned by expanding innovative drug pipelines, rising overseas licensing revenues, and the growing elderly population's demand for pharmaceuticals and healthcare services, is set to fuel sustainable growth and higher net margins within its healthcare business.
Want to see what sits behind that HK$5.08 fair value for Fosun International? The narrative leans heavily on improving margins, steadier revenue growth and a higher future earnings multiple. The exact mix of those inputs might surprise you.
Result: Fair Value of HK$5.08 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Fosun International still faces pressure from high debt and refinancing needs, and weaker consumer and manufacturing segments could weigh on the otherwise positive profit narrative.
Find out about the key risks to this Fosun International narrative.
Next Steps
With sentiment on Fosun International clearly split between opportunity and concern, this is a good moment to move quickly and weigh the evidence for yourself. You can start with the 3 key rewards and 1 important warning sign.
Looking for more ideas beyond Fosun International?
Do not stop with a single opportunity. Use the Simply Wall Street Screener to uncover other stocks that fit the kind of portfolio you want to build.
- Target potential mispricings by checking stocks that currently look beaten down yet financially sound through the 250 high quality undervalued stocks.
- Strengthen your income stream by reviewing companies that feature the 439 dividend fortresses.
- Focus on quality first by filtering for companies highlighted in the 302 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com